Key Takeaways
- Stellantis (STLA) reported preliminary Q2 shipments down 6% year-over-year to 1.4 million units, with North American shipments plummeting 25%, contributing to an estimated H1 net loss of €2.3 billion.
- AstraZeneca (AZN) announced that its drug Tagrisso, combined with chemotherapy, demonstrated statistically significant and clinically meaningful improvement in overall survival for patients with EGFR-mutated advanced lung cancer in the FLAURA2 trial.
- Roche (RHHBY) faced a setback as its experimental drug, astegolimab, for Chronic Obstructive Pulmonary Disease (COPD) yielded mixed results in late-stage trials.
Stellantis (STLA) has released preliminary financial figures for the first half of 2025, revealing a challenging period. The automotive giant reported an estimated net loss of €2.3 billion for H1, alongside negative industrial free cash flows of €3.0 billion and an adjusted operating income estimated at €0.5 billion.
In the second quarter, Stellantis's global shipments declined 6% year-over-year to 1.4 million units. North America experienced a significant drop, with shipments down 25% year-over-year to 322,000 units. Despite the declines in shipments, Q2 net revenues are estimated at €74.3 billion.
On the pharmaceutical front, AstraZeneca (AZN) delivered positive news regarding its lung cancer treatment. The company announced that its drug Tagrisso (osimertinib), when combined with chemotherapy, showed a statistically significant and clinically meaningful improvement in overall survival for patients suffering from EGFR-mutated advanced lung cancer. These promising results stem from the FLAURA2 Phase III trial and indicate a favorable trend toward overall survival improvement at two years of follow-up, alongside a manageable safety profile.
Conversely, Roche (RHHBY) encountered mixed outcomes for its experimental drug astegolimab, intended for the treatment of a deadly lung condition, specifically Chronic Obstructive Pulmonary Disease (COPD). While one Phase 2b study showed a 15.4% reduction in exacerbations (worsening of the condition), the drug ultimately failed to meet its primary goal in another trial. This represents a setback for Roche as it continues efforts to accelerate the development of new treatments.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.